Travere Therapeutics
TVTX
130 hedge funds and large institutions have $516M invested in Travere Therapeutics in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 17 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
7% more funds holding
Funds holding: 122 → 130 (+8)
1.41% less ownership
Funds ownership: 105.01% → 103.6% (-1.4%)
29% less call options, than puts
Call options by funds: $6.19M | Put options by funds: $8.72M
41% less capital invested
Capital invested by funds: $874M → $516M (-$358M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$65.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.84M |
| 4 |
Renaissance Technologies
New York
|
+$6.85M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$4.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$24.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$17.6M |
| 3 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$12.3M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$11M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.54M |
TVTX Hedge Fund Activity: Q3 2019 in Review
130 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2019, worth a combined $516M — down 41% from $874M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TVTX positions and 17 closed out — a net gain of 8 holders — while 54 added to existing stakes and 32 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $65.9M. The largest seller was Consonance Capital Management, cutting an estimated $24.8M.
- 130 institutional investors held Travere Therapeutics (TVTX) as of Q3 2019, up from 122 in Q2 2019.
- Funds reported $516M of Travere Therapeutics stock for Q3 2019, down 41% quarter-over-quarter.
- 25 funds opened new Travere Therapeutics positions in Q3 2019 and 17 closed out, a net change of +8 holders.
- The largest Travere Therapeutics buyer in Q3 2019 was RA Capital Management, an estimated $65.9M added.
- The largest Travere Therapeutics seller in Q3 2019 was Consonance Capital Management, an estimated $24.8M sold.
Based on aggregated 13F filings for Q3 2019.